Management of Heavy Menstrual Bleeding After Nexplanon Implant

Initial Assessment

Clinicians should first discuss the patient’s preference for continuing versus removing the implant and screen for pregnancy, sexually transmitted infections, thyroid disorders, or new uterine pathology (e.g., polyps, fibroids) before initiating treatment. 2

The CDC (2024) recommends a 5‑ to 7‑day course of non‑steroidal anti‑inflammatory drugs (NSAIDs such as ibuprofen, celecoxib, or mefenamic acid) as the initial therapy for heavy or prolonged bleeding in patients who wish to retain the Nexplanon implant. 1
For spotting or light bleeding, the CDC advises that the same 5‑ to 7‑day NSAID regimen may be repeated as needed. 2

If bleeding persists after NSAIDs, the CDC recommends a short (10‑ to 20‑day) course of low‑dose combined oral contraceptives or estrogen as second‑line therapy. 2
Tranexamic acid administered for 5 days is an alternative second‑line option when hormonal treatment is not desired. 1
Selective estrogen receptor modulators (e.g., tamoxifen) given for 7‑10 days are listed by the CDC as agents that may provide longer‑lasting reduction in bleeding. 1
When NSAIDs fail or rapid bleeding cessation is critical, the CDC permits use of combined oral contraceptives despite their higher systemic hormonal exposure. 1

If bleeding remains unacceptable after pharmacologic attempts, the CDC recommends offering implant removal, providing counseling on alternative contraceptive methods, and initiating a new method if the patient desires. 2